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Immune adaptor SKAP1 acts a 
scaffold for Polo-like kinase 1 
(PLK1) for the optimal cell cycling 
of T-cells
Monika Raab1,2, Klaus Strebhardt1 & Christopher E. Rudd2,3,4
While the immune cell adaptor protein SKAP1 mediates LFA-1 activation induced by antigen-receptor 
(TCR/CD3) ligation on T-cells, it is unclear whether the adaptor interacts with other mediators of T-cell 
function. In this context, the serine/threonine kinase, polo-like kinase (PLK1) regulates multiple steps in 
the mitotic and cell cycle progression of mammalian cells. Here, we show that SKAP1 is phosphorylated 
by and binds to PLK1 for the optimal cycling of T-cells. PLK1 binds to the N-terminal residue serine 31 
(S31) of SKAP1 and the interaction is needed for optimal PLK1 kinase activity. Further, siRNA knock-
down of SKAP1 reduced the rate of T-cell division concurrent with a delay in the expression of PLK1, 
Cyclin A and pH3. Reconstitution of these KD cells with WT SKAP1, but not the SKAP1 S31 mutant, 
restored normal cell division. SKAP1-PLK1 binding is dynamically regulated during the cell cycle of 
T-cells. Our findings identify a novel role for SKAP1 in the regulation of PLK1 and optimal cell cycling 
needed for T-cell clonal expansion in response to antigenic activation.
Polo-like kinase 1 (PLK1) is a serine/threonine kinase that regulates the mitosis of mammalian cells. It is a mem-
ber of the Polo-like serine/threonine kinase (PLKs) family that are structurally conserved from yeast to mam-
mals. Structurally, they are comprised of a kinase domain at the N-terminus as well as polo-box domain at the 
C-terminus1,2. There are five different PLK family members expressed in mammalian cells where they regulate 
the cell cycle2. PLK1-deficient mice show early embryonic lethality with a failure to progress beyond the 8-cell 
stage3. PLK1 is expressed by primary T-cells4 and regulates multiple stages of mitosis4,5. In this context, PLK1 
expression varies with different stage of the cell cycle, accumulating to maximal levels during G2 and M phases5–7. 
At mitosis, PLK1 activates phosphatase Cdc25C, a positive regulator of Cdc2/Cyclin B1 complex7. Cdc2/Cyclin 
B1 in turn is a cyclin-dependent kinase that regulates G2/M phase transition8. Beyond this, PLK1 also contrib-
utes to the mitotic exit by regulating the anaphase-promoting complex (APC)9. It is localized at centrosomes 
during inter-phase and prophase but is found at the kinetochore during pre-metaphase and metaphase. During 
anaphase, PLK1 relocates to spindles, and in the mid-body during telophase6,10. These different locations correlate 
with distinct functions for PLK1 during mitotic progression. PLK1 can directly promote entry into mitosis by 
activating Cdc25C and Cdk1/Cyclin B1, while increasing microtubule nucleation with the phosphorylation of 
Nlp, Kizuna and Asp11. In addition, PLK1 regulates kinetochore functions and the spindle assembly checkpoint 
by an interaction with other distinct proteins, INCENP, Bub1 and BubR112–14. Further, PLK1 is needed for cytoki-
nesis due to its regulation of Ect2 and RhoA15.
Importantly, the altered expression of PLK1 can induce defects in mitosis that result in aneuploidy and tum-
origenesis16–19. Different cancer cell lines carry missense mutations of PLK120. In one case, mutations in the 
C-terminal PBD act to suppress the interaction between PLK1 and HSP9020. PLK1 is expressed in cutaneous 
T-cell lymphomas (CTCLs)21 where its down-regulation promotes cell cycle arrest and apoptosis22.
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Immune cell adaptors also regulate T-cell proliferation and function23,24. SLP-76 (SH2 domain containing leu-
kocyte protein of 76 kDa) is one such adaptor that is needed for phospholipase Cγ1 (PLCγ1) activation, calcium 
mobilization and thymic differentiation25,26. It has an N-terminal sterile-α motif (SAM) and a carboxy-terminal 
SH2 domain that binds to adhesion and degranulation-promoting adapter protein (ADAP)27–31 and the hemato-
poietic progenitor kinase-1 (HPK-1)31. The C-terminal SH2 domain SLP-76 binds to the ADAP27,28,32, while 
ADAP in turn binds to SKAP132,33. SKAP1 is an adaptor with a unique N terminus, a PH domain and a C termi-
nal SH3 domain33. SKAP1 SH3 domain binds to proline residues in ADAP while the ADAP-SH3-like domain 
binds to SKAP134,35. SKAP1 couples the TCR to the activation of LFA-135–40. SKAP1 regulates RapL-Rap1 binding 
induced by antigen-receptor ligation41–46 and is also connected to Rap1-RIAM35,47.
In this study, we show that PLK1 phosphorylates and binds to SKAP1, an interaction that is cell cycle depend-
ent during mitosis. Further, we show that SKAP1 regulates PLK1 kinase activity and that the binding between 
SKAP1 and PLK1 is needed for optimal T-cell cell division. Our findings identify a novel role for SKAP1 as a 
scaffold for PLK1 in the regulation for the cell cycle of T-cells.
Materials and Methods
Cell culture. Jurkat cells were obtained from the American Type Culture Collection (ATCC), while the 
T8.1 mouse hybridomas were cultured in RPMI 1640 media containing 10% fetal calf serum (FCS). 293T and 
Hela cells were grown in DMEM media. Both RPMI 1640 and DMEM media were supplemented with 2 mM 
L-glutamine and penicillin/streptomycin.
Antibodies. Anti-mouse CD3 (145-2C11) was from American Type Culture Collection while anti-GFP and 
anti-GST were from Santa Cruz. Anti-SKAP1 (BD Transduction Laboratories), anti-Myc (Cell Signaling), anti-V5 
(Invitrogen), anti-FLAG and anti-β-Actin (Sigma) were purchased as assigned. Mouse monoclonal antibodies 
used in blotting included PLK1 (1:1,000; Cell Signaling), CDK1 (1:1,000; Millipore), Cyclin B1 (1:1,000; Sigma), 
Cyclin A (1:1000; Cell Signaling), β-Actin (1:200,000; Sigma), phospho-Histone H3 (S10) (1:1,000; Millipore). 
HRP-conjugated secondary antibodies (1:5,000) were purchased from the The Jackson Laboratory (Maine). 
Recombinant kinases PLK1, PLK3, CDK1, CDK2, MAPK, Aurora B, CAMK and ZAP-70 were from ProQuinase. 
Histone H1 protein were obtained from Biolabs).
Constructs and transfection. Full-length and fragments of human SKAP1 cDNA were sub-cloned into 
the pGEX vector as described (Raab et al.42). These included full-length SKAP1, N-terminal (N-SKAP1; residues 
1–104), SK region (SK; residues 209–285), or N plus PH and SK regions (N-PH-SK; residues 1–285) were inserted 
into a pGEX5x-3 (GE Healthcare) as well as cloned into a Flag-tagged (3 times tag) and an EGFP-tagged pcD-
NA3.1-Hygro (Invitrogen) vector. Site-directed mutagenesis was employed using QuickChange and Pfu Ultra II 
Fusion HS DNA Polymerase (Stratagene). The sequence of constructs was each confirmed by in house sequencing 
(Frankfurt). The PLK1 constructs were then inserted into the 3xFlag-tagged vector. Transfections of Jurkat and 
T8.1 mouse hybridomas were subsequently performed by electroporation using a BTX ECM 830 electropora-
tor. Transfected cells were transferred to prewarmed complete medium and cultured for 24 hours of recovery. 
Transfection of 293T cells were performed with Jet Pei according to the manufacturer’s instructions.
In situ proximity analysis. DuolinkTM was used to conduct in situ proximity analysis with DuolinkTM in 
situ PLA reagents as described previously44. Briefly, Duolink Blocking was followed by the use of anti-PLK1 and 
anti-SKAP1 and isotype specific secondary antibodies in Antibody Diluent42. Duolink ligation with ligase was 
followed by amplification with Duolink Amplification stock and polymerase at 37 °C.
Immunoprecipitation and blotting. Precipitation was conducted by solublization of cells in Triton X-100, 
antibody incubation and precipitation with protein G-Sepharose beads, as described48–50. Precipitates were run 
on SDS-PAGE followed by a transfer to nitrocellulose for immunoblotting41. Horseradish peroxidase-conjugated 
rabbit anti-mouse antibody was used together with enhanced chemiluminescence (Amersham Biosciences) for 
detection of transferred proteins.
GST pull down assay. GST-proteins were expressed in a standard manner in Escherichia coli BL21 cells with 
1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG), as described42. Cell Lytic B protocol was used to purify the 
GST-fusion proteins (Sigma #B7435).
Kinase assay. In vitro kinase assays were performed using 10x PK buffer (New England Biolabs) supple-
mented with 0.05 mM ATP and 1 μATP and γ32-ATP (3,000 Ci/mmol; Amersham Pharmacia) for 30 min at 37 °C 
in the presence of recombinant human active kinase (ProQuinase) and bacterially expressed purified GST pro-
teins as substrates.
Construction of SKAP1 shRNA vectors. The template for human-mouse–SKAP1 shRNAs was gen-
erated by ligating the annealed primers 5′-ACCTCACATTGGACAGGACAGCTCTGTCAAGAGCAGA 
GCTGTCCTGT CCAATGTTT-3′ and 5′-CAAAAAACATTGGACAGG ACAGCTCTGCTCTTGACA 
GAGCTGTC C TGTC CAATGTG-3 ′  ( for  W1 and Z1) ,  and 5 ′ -C CTCATAAC GTAATCAA 
G C A AG  G AT T C A AG AG AT  C C T T G C T T G AT TAC G T TAT T T- 3 ′  a n d  5 ′ - C A A A A A AT 
AACGTAATCAAGCAAGGATCTCTTGAATCCTTGCTTGATTACGTTATG-3′ (for W3 and Z3) into the BbsI 
sites of psiRNA-hH1 vectors (InVivo Gen). As a control, the primers 5′-ACCTCGCGTTAATTAGACTGAGGA 
GTTCAAGAGAC TCCTCAGTC TAATTAACGCTT-3 ′  and 5 ′-CAAAAAGCGTTAATTAGAC 
TGAGGAGTCTCTTG AACTCCTCAGTCTAATTAACGCG-3′ were used. Designed RNA oligonucleotides 
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were blasted against the GenBank/EMBL/DDBJ database to ensure gene specificity. This nonrelevant control had 
no homology with mouse SKAP1 genes.
Synchronization and cell-cycle distribution by FACS analysis. For cell cycle studies, cells were incu-
bated in the presence of 2 mM thymidine (Sigma; 16 h), released in fresh medium (8 h) and then subjected to a 
second thymidine block (16 h) as described previously17. For FACs, cells were collected after every 3 h to assess 
changes in cell-cycle kinetics. Cell-cycle quantification of flow cytometry data (FACScan, BD Biosciences) was 
conducted using ModFit (Verity Software House). 150 nM Nocodazol (Sigma) for 16 hours was used to arrest 
cells in mitosis.
Results
PLK1 phosphorylates N-terminal sites on SKAP1. To assess a connection between serine/threonine 
kinases and SKAP1, an array of kinases was tested for an ability to phosphorylate SKAP1 (Fig. 1a). Purified GST-
SKAP1 was added to precipitates of individual kinases that included CDK1, CDK2, MAPK, Aurora B, CAMK, 
PLK3, PLK1, MST1 and ZAP-70 in the presence of radio-active phosphate followed by an assessment of phospho-
rylation on SDS-PAGE. From this, we observed that PLK1 was the only kinase to phosphorylate the GST-SKAP1 
(lane 7). Coomassie Blue staining showed the presence of equal amounts of GST-SKAP1 (lower panel). To map 
the site of phosphorylation, purified GST-fusion proteins of different regions of SKAP1 and SKAP1 full-length 
WT were incubated with purified PLK1 kinase in an in vitro phosphorylation assay (Fig. 1b). The GST fusion 
Figure 1. PLK1 phosphorylates the N terminal, PH and SK regions of SKAP1. (Panel a) PLK1 phosphorylates 
SKAP1. Purified GST-SKAP1 was added to purified recombinant kinases that included CDK1, CDK2, MAPK, 
Aurora B, CAMK, PLK3, PLK1, MST1 and ZAP-70 in the presence of radio-active phosphate followed by an 
assessment of phosphorylation on SDS-PAGE (upper panel). Coomassie blue staining of GST-SKAP1 (lower 
panel). (Panel b) PLK1 phosphorylates the N terminal, PH and SK regions of SKAP1. As above, incubation with 
fusion proteins of various regions of SKAP1 with recombinant PLK1 in the presence of γ32-ATP. Coomassie blue 
staining of the various GST-SKAP1 constructs. (Panel c) BI2536 inhibits PLK1 phosphorylation of N terminal 
SKAP1. Jurkat T cells were incubated with increasing amounts of the PLK1 Inhibitor BI2536 for 24 hours, 
followed by immunoprecipitation using anti-PLK1 and in vitro kinase assay with GST-SKAP1-N-terminal 
domain.
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proteins included full-length SKAP1, N-terminal (N-SKAP1; residues 1–104), SK region (SK; residues 209–285), 
or N plus PH and SK regions (N-PH-SK; residues 1–285). From this, all proteins with the N-terminus or the SK 
region of SKAP1 were phosphorylated by PLK1 (middle panel). By contrast, PLK1 failed to phosphorylate the 
GST-SKAP1 SH3 domain. Coomassie Blue staining of the gels confirmed the presence of the GST fusion proteins 
(lower panel). Further, the small molecule PLK1 inhibitor BI2536 inhibited the phosphorylation of GST-SKAP1 
N in anti-PLK1 precipitates from Jurkat T-cells by as much as 60% (lower panel) (Fig. 1c). These data showed that 
PLK1 can mediate the in vitro phosphorylation of several regions in SKAP1.
We then identified potential phosphorylation sites based on the PLK1 consensus sequence (D/E-XX-(S/T)-X-
(D/E) in human SKAP1 (Johnson et al. 2007; Nakajima et al. 2003) (Fig. 2a). Sites include S31: ENL-S-AVARD; 
S118: EKK-S-KD; S122: KDH-S-FF; S182: ELT-S-QDR and T213: EE-T-YDD. To examine potential sites, 
full-length and N-terminal fragment of (residues 1–104) human SKAP1 cDNA were sub-cloned into the pGEX 
vector as described42. GST fusion protein wild-type SKAP1 and N-terminal deletion mutants were then used 
in an in vitro kinase assay with PLK1 (Fig. 2b). Mutation of residue 31 in the N- terminal domain (i.e. S31A) of 
SKAP1 reduced phosphorylation relative to N-terminal wild-type SKAP1 (lanes 1–2). By contrast, mutation of 
residues S118A, S122A and S182A within the GST-SKAP1-NPH domain construct had no effect on its phospho-
rylation (lanes 3–6). GST-SKAP1-NPH fusion proteins were less well phosphorylated than the N-domain protein. 
The phosphorylation of T231A mutant in the SK domain was unaffected relative to wild-type GST-SKAP1 SK 
(lanes 7, 8). Similarly, a GST-SKAP1-N fusion protein was phosphorylated (Fig. 2c), while mutation of S31A 
reduced this phosphorylation (lane 2 vs 1). Constructs of residues 1–78 or 1–62 containing the S31A mutant were 
Figure 2. PLK1 phosphorylates the S31 site in SKAP1 N-terminal region. (Panel a) Sequence of SKAP1 
showing putative PLK1 phosphorylation sites. (Panel b) PLK1 phosphorylates GST- SKAP1-S31. Purified GST-
fusion proteins of different regions in SKAP1 were incubated with purified recombinant PLK1 kinase in an  
in vitro phosphorylation assay. The GST fusion proteins included SKAP1, N-terminal (N-SKAP1; residues 
1–104), N-SKAP-S31A, SK region (SK; residues 209–285), SK-T231A or N plus PH; N-PH S118A, N-PH 
S122A, N-PH, S182A. (Panel c) PLK1 phosphorylates GST-SKAP1-S31A. GST-fusion proteins as outlined were 
incubated with purified PLK1 kinase in an in vitro phosphorylation assay. Panel d: Full-length GST-SKAP1-WT 
and S31A mutant were incubated with recombinant PLK1 kinase in an in vitro phosphorylation assay. 
Coomassie blue staining shows equal loading.
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resistant to phosphorylation (lanes 3, 4). Lastly, the GST-SKAP1-WT-S31A underwent less phosphorylation than 
GST-SKAP1-WT in an in vitro kinase assay (Fig. 2d). Commassie staining showed the presence of equal amounts 
of the fusion proteins. Overall, these observations indicated that serine 31 was a key phosphorylation site in 
SKAP1 for PLK1.
SKAP1 N-terminus binds to the PLK1 kinase domain. To assess whether PLK1 binds to SKAP1, we 
first ran a proximity ligation assay (PLA) of endogenous proteins in Jurkat cells to determine whether the two 
proteins localize in close proximity (Fig. 3a). This assay showed that anti-PLK1 and anti-SKAP1 generated posi-
tive signals indicative of a close association, no signal was detected when both antibodies were used alone. Similar 
PLA signals have been observed between other proteins in the lab previously44. Consistent with this observation, 
anti-SKAP1 co-precipitated endogenous PLK1 from Jurkat T-cells (Fig. 3b, lane 2) ad anti-PLK1 co-precipitated 
SKAP1 (lane 4). Further, Hela cells were co-transfected with either PLK1, RIAM, LAT or SKAP1 tagged with 
FLAG in combination with Myc-tagged PLK1 (Fig. 3c). Anti-Myc co-precipitated SKAP1, but not the RIAM or 
LAT controls (lane 4 vs. 2, 3). It also co-precipitated Flag-PLK1 indicating that it can bind to itself (lane 1). Lower 
panels show the expression controls for various expressed proteins. These data showed that PLK1 can bind to 
SKAP1 in mammalian cells.
To map the binding regions between the two proteins, GST fusion proteins of regions in SKAP1 were used 
to co-precipitate endogenous PLK1 from lysates of Hela cells (Fig. 4a, upper panel). The SKAP1 N domain 
Figure 3. PLK1 binds to SKAP1. (Panel a) Proximity ligation assay (PLA) of endogenous PLK1 and SKAP1 in 
Jurkat T-cells shows a positive signal. (Panel b) Anti-PLK1 co-precipitates SKAP1 and vice versa. Lane 1: lysate; 
lane 2: anti-SKAP1; lane 3: anti-rabbit control; lane 4: anti-PLK1; lane 5: anti-mouse control. (Panel c) Anti-
PLK1 co-precipitates SKAP1 from transfected Hela cells. Hela cells were transfected with either PLK1, RIAM, 
LAT or SKAP1 tagged with FLAG in combination with Myc- tagged PLK1. Anti-Myc co-precipitated SKAP1, 
but not the RIAM or LAT controls (lane 4 vs. 2, 3). It also co-precipitated Flag-PLK1 indicating that it can bind 
to itself (lane 1). Lower panels show the expression controls for various expressed proteins.
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co-precipitated PLK1 (lane 3), and further, mutation of S31A in this region disrupted the co-precipitation (lane 
4). Neither the SKAP1 SK or SH3 domain was able to co-precipitate PLK1 (lanes 5 and 6, respectively). S31 is 
conserved in mouse and human SKAP1. Further, mutation of S31 in full-length SKAP1 also disrupted the inter-
action with PLK1 (Fig. 4a, lower panel, lane 4 vs lane 3). These data indicated that the N terminal region of SKAP1 
interacted with PLK1.
Conversely, Flag-tagged PLK1, N-terminus-kinase domain (NKD) or the PBD domains were expressed with 
GFP-tagged SKAP1 in the cell line, 293T (Fig. 4b). Anti-SKAP1 co-precipitated Flag tagged PLK1 WT (lane 4) 
and the NKD protein (lane 5), and not to the PBD domains (lane 6). Anti-Flag precipitation of PLK1 PBD also 
failed to precipitate GFP-SKAP1. These data indicated that the N terminal region of SKAP1 interacted with the 
PLK1 kinase domain.
SKAP1 binding activates PLK1 kinase activity. Given this interaction, an important question was 
whether SKAP1 binding might affect PLK1 kinase activity (Fig. 5). To assess this, SKAP1 full-length WT or the 
binding mutant S31A were co-expressed with PLK1 in Hela cells. Cell growth was arrested in mitosis using an 
inhibitor of microtubule dynamics nocodazole (Noc) followed by an assessment of PLK1 activity (Fig. 5a). Cells 
arrested in mitosis by Noc showed a similar level of PLK1 expression in cells expressing vector (Mock), WT and 
S31A SKAP1 (upper panel). Despite this, the precipitation of PLK1 followed by a measure of in vitro kinase activ-
ity of PLK1 using the phosphorylation of histone 1 as a target substrate showed a >50% reduction in PLK1 kinase 
activity in cells expressing the S31A mutant (middle panel, lane 6 vs. 4, 5 and lower histogram). A similar level of 
Figure 4. Binding sites between PLK1 and SKAP1. (Panel a) Upper panel::SKAP1 S31 in the N-terminal 
domain binds PLK1. GST fusion proteins of regions in SKAP1 were used to co-precipitate endogenous PLK1 
from lysates of Hela cells. Mutation of S31A in this region disrupted the interaction. Lane 1: lysate; lane 2: 
GST; lane 3: GST-SKAP1-N; lanes 4: GST-SKAP1-S31A; lane 5: GST-SKAP1-SK; lane 6: GST-SKAP1-SH3. 
Lower panel: GST full-length proteins of SKAP1 WT and S31A mutant were used to co-precipitate Flag-PLK1 
expressed in 293T cells. Lane 1: lysate; lane 2: GST; lane 3: GST-SKAP1 WT; lane 4: GST-SKAP1-S31A. GST-
Blot shows equal expression. (Panel b) SKAP1 binds to the NKD kinase domain of PLK1. Co-expression in 
293T cells of either Flag-tagged PLK1, N-terminus-kinase domain (NKD) or the PBD domains with GFP-
SKAP1. Middle panel: GFP-SKAP1 readily co-precipitated wild type PLK1 (lane 4) and the NKD protein (lane 
5), and not to the PBD domains (lane 6). Lower panel: Flag-PLK1 PBD failed to precipitate GFP-SKAP1.
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SKAP1 WT and S31A was expressed in the cells as well as beta actin as an additional control (lower panel, lanes, 2, 
3, 5 and 6). These data showed that SKAP1 binding to PLK1 is needed to increase in PLK1 activity in mitotic cells.
We further used purified recombinant GST-PLK1 from baculoviral expression with precipitated Flag-SKAP1 
full-length WT, or the S31A mutant, in the presence of GST-CRS, the cytosolic retention sequence of Cyclin B1, 
as a substrate, in an in vitro kinase assay (Fig. 5b). While SKAP1 WT increased the kinase activity of recombinant 
PLK1, the S31A mutant failed to activate PLK1 autophosphorylation or GST-CRS phosphorylation. These data 
further demonstrated that SKAP1 residue S31 binding to PLK1 was needed for the activation of PLK1.
Figure 5. SKAP1 binding regulates PLK1 activity. (Panel a) SKAP1 WT or binding mutant S31A and PLK-1 
were co-expressed in Hela cells. Cell growth was arrested in mitosis using 150 nM nocodazole for 16 hours 
followed by a measure PLK1 activity. Upper panel: Nocodazol induced a similar increase in the expression of 
PLK1 in cells expressing vector (Mock), WT and S31A SKAP1. Middle panel: Precipitation of PLK1 followed 
by a measure of in vitro kinase activity of PLK1 using the phosphorylation of histone 1 as a target substrate. 
Coomassie blue staining show equal loading. PLK1 kinase activity in cells expressing the S31A mutant was 
reduced (lane 6 vs. 4, 5). Middle panel: a similar level of SKAP1 WT and S31A was expressed in the cells. 
Lower panel: Histogram showing intensity of histone 1 phosphorylation in %. (Panel b) Recombinant PLK1 
kinase was incubated with purified Flag-SKAP1 WT and S31A mutant expressed in 293 T and GST-CRS 
(cytosolic retention signal of Cyclin B1) as substrate for 30 min, 37 °C in the presence of γ32p-ATP. Anti-Flag 
blot shows equal expression of FLAG-SKAP1 and S31A mutant. PLK1 auto-phosphorylation and GST-CRS 
phosphorylation was reduced in the presence of S31A mutant. (Panel c) Down-regulation of SKAP1 expression 
in mouse hybridoma T 8.1 cells (Z14) shows reduced PLK1 kinase activity. PLK1 was immunoprecipitated from 
detergent lysates of T8.1 cells and used in an in vitro kinase assay with GST-CRS. Anti-PLK1 immunoblot which 
shows similar levels of immunoprecipitated PLK1. Anti-SKAP1 blot shows down-regulation of SKAP1.
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Next, we performed anti-PLK1 immunoprecipitations from T8.1T WT-cells and Z14 cells where SKAP1 
had been knocked-down using shRNA51 (Fig. 5c). While anti-PLK1 showed PLK1 activity as seen by its 
auto-phosphorylation and phosphorylation of GST-CRS, PLK1 phosphorylation of itself and substrate was mark-
edly reduced in Z14 cells (middle panels). As controls, blotting with anti-PLK1 showed equal level of expression, 
while blotting with anti-SKAP1 showed the loss of SKAP1 expression in the Z14 cells (lower panels). These data 
confirm further that SKAP1 expression is needed for optimal PLK1 activation.
SKAP1 interacts with PLK1 during mitosis. Given the role of PLK1 in regulating cell division and the 
ability of SKAP1 to influence PLK1 activity, we next assessed whether the binding of PLK1 to SKAP1 occurs dur-
ing and following mitosis. Jurkat T-cells were incubated with Noc to synchronize the cells in mitosis (Fig. 6). Most 
of the blocked cells had a 4N status in G2/M, while the release was followed by the progression to 2N in G0/G1 
over 2–6 hours (Fig. 6a, left panel). Precipitation with anti-SKAP1 from cell lysates following the release showed 
the co-precipitation of PLK1 with SKAP1 from 0–2 hours (right upper panels). Anti-SKAP1 co-precipitated PLK1 
from 0–2 hours post-release followed by a progressive reduction from 4–8 hours. As a control, the blotting of cell 
lysates showed a sustained expression of PLK1, SKAP1 and β-Actin over this time frame (lower panels). PLK1 
Figure 6. Interaction of SKAP1 and PLK1 is regulated following arrested mitosis. (Panel a) Jurkat T-cells were 
incubated with 150 nM nocodazole for 16 hours and released in fresh media for 8 hours and analyzed by FACS 
and Western blotting. Mitotic arrested cells at 0 hour showed a 4N status in G2/M (left panel). Washing the 
cells and their release from blockade was followed by the progression to 2N in G0/G1 over 2–8 hours. Right 
panel: Anti-SKAP1 co-precipitation of PLK1 with SKAP1 following release from mitotic arrest. Lower panels: 
Blotting of cell lysates with anti-PLK1, SKAP1 and β-Actin. (Panel b) Jurkat cells were synchronized by double 
thymidine treatment and analyzed by Western blotting with antibodies against SKAP1, PLK1, Cyclin B1, Cyclin 
A, pHistone, H3 and β-Actin.
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expression was highest from 0–6 hours. As a further control, we monitored the expression of SKAP1, PLK1 reg-
ulators of cell cycle at various stages of mitosis (Fig. 6b). SKAP1 was expressed at its highest level during S and 
early G2/M and late G0/G1, while PLK1 was expressed mostly during G2/M and G0/G1. Cyclin B1 was expressed 
mostly during M-phase and Cyclin A during S-G2 and pH3 during M-phase as expected. Overall our data showed 
that SKAP1 expression and its binding to PLK1 is dynamically regulated during the cell cycle of T-cells.
T-cells with reduced SKAP1 showed a delayed onset of G2/M. These above data suggested the 
SKAP1-PLK1 contributes to the efficiency of the cycling of T-cells. Initially, the cycling of shRNA KD Z14 cells 
were contrasted with wild-type cells51 (Fig. 7a, top left inset). Cells were subjected to double thymidine (DT) 
synchronization to monitor the kinetics of cell cycle progression. Indeed, SKAP1 KD Z14 T-cells showed a 
slower rate of cell cycle progression (top right inset). While S phase commenced at the same time for both cells 
post-block (0–3 hours), a delay of 3–6 hours was seen in Z14 cells (lower histogram). Strikingly, by 6 hours, >65% 
of WT cells had entered in G2/M phase while 12% of Z14 had entered this phase. Z14 cells entered G2/M over 
a more extended period with 20–25% by 12 h and 18% by 12 hours. Similarly, Z14 cells were delayed in entry to 
S phase when compared to WT cells. These data showed the reduction in SKAP1 expression retards cell cycle 
progression in T-cells.
Next, we examined the expression of regulators of cell cycle such as Cyclin B1 (M phase), Cyclin A (S-G2 
phase) and phospho-Histone H3 (pH3) (M phase) in wild-type cells versus Z14 cells (Fig. 7b). Consistent with the 
delay in cell cycling, the expression of the PLK1, Cyclin B1, Cyclin A and pH3 in Z14 cells was delayed by some 
3–6 hours relative to wild-type cells. The expression of PLK1 peaked at 3–9 hours in WT cells and at 6–12 hours 
in Z14 cells. The expression of Cyclin B1 and pH3 of M phase was observed 0–6 hours in wild-type cells and 
at 6–12 hours in Z14 cells. As a control, no effect was seen on the expression of β-Actin. Consistent with these 
observations, the reduction in SKAP1 expression reduced significantly the cell growth rate as seen by the reduced 
numbers of Z14 cells in culture at 72 and 96 hours (Fig. 7c). For example, at 96 hours, there were 30% fewer Z14 
cells that WT T-cells. These data further show that SKAP1 promotes the cell cycle progression of T-cells.
Lastly, it was important to examine whether the interaction between SKAP1 and PLK1 controlled the effi-
cacy of cell division (Fig. 7d). For this, we performed rescue experiments by transfecting Z14 cells with either 
Flag-SKAP1 WT, or the Flag-SKAP1 S31A mutant. Flag-SKAP1 WT expression in Z14 cells was able to rescue 
the cell cycle progression to that seen in WT cells. By contrast, the Flag-SKAP1 S31A mutant failed to restore the 
pattern of cell progression seen in WT cells. For example, by 6 hours, 48–55% of WT T8.1 and reconstituted Z14 
WT cells entered G2M, while only 15–22% of Z14 or Flag-SKAP1 S31A reconstituted cells had entered by this 
time. The expression of both constructs was also monitored during the cell cycle after double thymidine block 
with anti-Flag antibodies (Fig. 7e). Peak expression of PLK1 was seen at 6 hours in the WT and the Z14 expressing 
SKAP1, and at 9 hours in the Z14 and Z14 cells expressing SKAP1 S31A (upper panel). The expression of trans-
fected WT and Flag-SKAP1 S31A protein was similar during this period (lower panel). Overall, this data shows 
that the interaction between SKAP1 and PLK1 controls the efficacy of T-cell division.
Discussion
SKAP1 has previously been shown to activate LFA-1 following antigen-receptor ligation38,52. Whether this was the 
adaptors only function in the activation of T-cells had been unclear. Here, we define a second function for SKAP1 
involving the regulation of PLK1 activity and T-cell cycling. We found that SKAP1 was both bound to PLK1, 
mapped the binding region to the N-terminus-kinase domain of PLK1 and showed that SKAP1 is a substrate of 
PLK1. Further, we showed that SKAP1 binding regulated PLK1 kinase activity, and lastly, that the SKAP1-PLK1 
complex was needed for the optimal cycling and cellular expansion of T-cells. Overall, PLK1 is known to control 
a number of processes in the cell cycle by phosphorylating different substrates, our findings now identify a novel 
role for an immune cell specific mediator SKAP1 in the regulation of PLK1 and the cell cycle of T-cells.
We previously showed the SKAP1 could localize to the nucleus of T-cells, and for this reason, searched for 
nuclear kinases that phosphorylate the adaptor32. Remarkably, PLK1 phosphorylated SKAP1 under in vitro 
conditions where related PLK3, and a range of other kinases such as CDK1, CDK2, MAPK, Aurora B, CAMK, 
and MST1 failed to phosphorylate the substrate. The specificity was noteworthy given that PLK1 and PLK3 
are related (>35%) with conserved regulatory sites and a similar overall structure53. This suggested a specific 
kinase-substrate relationship between PLK1 and SKAP1. Further, PLK1 phosphorylated the SKAP1 at serine res-
idue 31 which served as a binding site for PLK1. This suggested the possibility that PLK1 regulates its own bind-
ing. It is unclear whether the phosphorylation of SKAP1 S31 site is needed for binding to occur, and whether the 
binding to SKAP1 is needed for PLK1 to phosphorylate adjacent SKAP-1 molecules. Indeed, SKAP1 can undergo 
dimer formation45,46, and so, PLK1 binding to one subunit could potentially act as a scaffold for the phosphoryl-
ation of the second associated subunit within the complex.
It is also noteworthy that the S31 residue is located in a region homologous to a coiled-coil domain in related 
SKAP-1R (SKAP-related or SKAPHOM)32,45,54. We had previously shown that this region binds to RapL, an 
immune cell isoform of the RASSF5 (Ras association domain family 5) family55 and is needed for the regulation 
of T-cell adhesion and motility42,43. Whether the PLK1 binding to SKAP1 competes or complements binding 
to the RapL complex remains to be determined. However, this is considered unlikely given that although the 
interactions occur in different regions of the T-cell. SKAP1-RapL binding and its subsequent binding to the cyto-
plasmic tail of the integrin LFA-1 occurs at the cell surface42–44, while SKAP1-PLK1 interacts in the nucleus. The 
interactions therefore are likely to occur temporally at different times and different locations of the cell. A similar 
multi-functional role of an immune cell adaptor in different regions of a cell has been seen with SLP-76 which 
regulates TCR proximal signaling need for calcium mobilization26,56 as well as binding to RanGAP1 of the nuclear 
pore complex for the transport of transcription factors into the nucleus of T-cells57.
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Figure 7. SKAP1 regulates cell cycle of T-cells. (Panel a) SKAP1 shRNA knock-down of T-cells delays T-cell 
cycle progression. Cells were subjected to double thymidine (DT) labelling to monitor the kinetics of cell 
cycle progression. Upper left inset: shows down-regulation of SKAP1 expression in T-cells by SKAP1 shRNA. 
Right upper panel: FACS profile of DT synchronized mouse WT (T8.1) and SKAP1 KD Z14 T cells. Middle 
lower panel: Histogram showing percentages of cells which were in the G0/G1, G2/M and S phase. (Panel b) 
SKAP1 shRNA knock-down T-cells show a delay in expression of key regulators or cell cycle progression. The 
expression of regulators of cell cycle such as Cyclin B1 (M- phase), Cyclin A (S-G2 phase), pH3 (M phase) in 
wild-type cells versus Z14 cells by immunoblotting of cell lysates. (Panel c) Growth curve of SKAP1 WT T cells 
and SKAP1 shRNA knock-down T cells over a period of 96 hours. Z14 T cells show a lower cell number relative 
to T8.1 WT cells. (Panel d) SKAP1 WT, but not SKAP1-S31A, rescues Z14 T-cells for normal cell cycle. Z14 
T cells, transfected with either Flag-SKAP1 WT or a S31A mutant, were synchronized by double thymidine 
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Our second major finding was that SKAP1 could regulate the kinase activity of PLK1. This effect was seen in 
kinase assays where the mutation of residue S31 of SKAP1 as well as the down-regulation of SKAP1 by shRNA 
resulted in a reduction in PLK1 catalytic activity. Activity was measured by PLK1 auto-phosphorylation as well 
as its phosphorylation of exogenous substrates histone H1 and GST-CRS. Moreover, these effects of SKAP1 
down-regulation or the binding mutant were either seen in reconstitution studies in Hela cells, as well as in in 
vitro kinase assays of anti-PLK1 precipitates from WT T8.1 vs. Z14 SKAP1 KD cells. The molecular basis for the 
activation of PLK1 is unknown but could be direct given that SKAP1 binds to the N-terminus-kinase domain 
(NKD) of PLK1. The crystal structure of PLK1 has shown that the two Polo box (PB) motifs which form an intra-
molecular dimer that is joined by two linkers which limits nucleotide hydrolysis58. Further structural studies of 
the SKAP1- PLK1 complex will be needed to clarify mechanism of regulation of PLK1 by SKAP-1 more fully. The 
binding site of SKAP1 is distinct from the binding sites of proteins like the heat shock protein 90 (HSP90) where 
mutations abrogate binding in the C-terminal PBD20. These different mechanisms enable the complex temporal 
control of PLK1 activity in cells.
In keeping with the functional importance of SKAP1-PLK1 interaction to cell cycling, the down-regulation 
of SKAP1 and the expression of the SKAP1 S31A mutant delayed on cell cycle of T-cells. Plk1 controls a num-
ber of processes throughout the cell cycle, including centrosome maturation6 mitotic entry59 chromosome seg-
regation60 and cytokinesis61 by phosphorylating different substrates. We found that cell cycle progression was 
postponed with the down-regulation of SKAP1 resulting in a reduction in the T-cell number by some 30% over 
96 hours. This was concurrent with a delay in the expression of PLK1, Cyclin A, and pH3. Further, in keeping with 
the importance of the interaction itself, we found that Flag-SKAP1 S13 mutant expression in Z14 knock-down 
cells failed to rescue cell cycle progression, while equivalent expression of Flag-SKAP1 WT restored normal cell 
cycling. SKAP1, therefore, adds to the aggregate signaling needed for T-cell cell cycling. In other words, while the 
interaction is not essential, it adds to aggregate signaling to make cell cycling more efficient. Due to its restricted 
expression to immune cells, the SKAP1 pathway appears to have evolved as an additional immune cell specific 
pathway by which immune cell receptors regulate T-cell division in response to foreign pathogens and cancer 
neoantigens.
Lastly, our findings define an additional role for SKAP1 as an immune cell adaptor with the capacity to reg-
ulate multiple functions in T-cells. SKAP1 regulates PLK1 kinase activity in addition to its role in the regulation 
of LFA-1 activation by anti-CD3 ligation35,36,41,42. It is also the first example of direct SKAP1 regulation of a serine 
and threonine kinase in T-cells. It is possible that these different functions operate at various stages of T-cell 
activation and in different subcellular locations in the T-cell. Further, the regulatory effect of SKAP1 on PLK1 
occurred in response to signals linked to mitotic arrest. This contrasts with the SKAP1 activation of LFA-1 which 
occurs directly in response to anti-CD3 ligation35,36,41,42. SKAP1 induced LFA-1 activation also depends on the 
strength of the TCR signal where it has its greatest effect on low affinity or TCR signals36. Further, SKAP1 can 
bind and activate the exchange factor RasGRP1 which, in turn, negatively regulates the p21ras-ERK pathway in 
T-cells62,63. In addition, SKAP1 associated ADAP regulates the NFkB pathway64. These observations underscore 
the multi-functional nature of these immune cell specific adaptors in the regulation of T-cell signaling. Further 
work will be needed to define the exact temporal involvement of this adaptor in regulating various stages on PLK1 
involvement in the expansion of T-cells and in different T-cell subsets65.
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